John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at Follow @JohnCFierce on Twitter.

Articles by John Carroll

Suicide stunner prompts Amgen to dump brodalumab for psoriasis, walk away from AstraZeneca

A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...

The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D

Some of the leaders in the field will be gathering for a special FierceBiotech panel discussion on clinical trial design and execution for cancer drugs at the upcoming annual meeting of BIO in Philadelphia on June 16.

Racing a crowded field, Amgen says migraine drug looks promising in PhII

Amgen says it got the positive data it was looking for from a Phase II study of AMG 334, one of several experimental migraine drugs that share the same target and are in the running to compete against an old generation of drugs on the market.

Eli Lilly to work with Sanford-Burnham on autoimmune diseases

Eli Lilly has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders.

The ASCO roundup: Thumbs down for Puma, up for Roche, mixed for Bristol-Myers

The curtain has been raised on the first act of the annual cancer drug lollapalooza at ASCO, with the first round of abstracts spotlighting a series of early winners and at least one big loser: Puma Biotechnology.

UPDATED: Ex-Genentech dream team garners $217M to launch neurodegenerative player Denali

A group of high-profile ex-Genentech execs has rounded up a monster $217 million A round to launch Denali Therapeutics with plans to tackle neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and ALS.

Sage steps up to a pivotal PhIII as brain seizure drug aces trial challenge

Sage Therapeutics has successfully wrapped a small Phase I/II study of its lead drug for rare brain seizures, coming out with a 77% response rate among evaluable patients that was a slight step up from its interim results last fall. That successful end to the study puts the biotech on the threshold of a pivotal study with a clear shot at a new drug approval that would thrust it into the commercial world.

PureTech's Gelesis scraps plans for a $60M IPO

A flood of IPOs can't raise every biotech boat. Gelesis has scrapped its plans for a $60 million IPO after evidently failing to find a big enough appetite for its stomach-filling particle approach to combating obesity.

Sanofi doubles down on Selecta collaboration, adding $300M in fresh incentives

Sanofi is taking its three-year-old development collaboration with Selecta Biosciences another big step forward, taking an option on a "negative vaccine" program for celiac disease and putting another $300 million on the table in prospective milestones and research support for a successful program.

Financier looks to parlay a $5M Alzheimer's deal into instant $172.5M IPO

Late last year, a newly formed Bermuda-based biotech struck a deal to in-license a shelved Alzheimer's drug from GlaxoSmithKline with plans to put it into Phase III. That late-stage study won't start until the fourth quarter, but the newborn biotech, now operating as Axovant Sciences, has filed for a $172.5 million IPO, looking to cash in fast on the still-sizzling market for biotech stocks.